Article

Tumor Intrinsic Mechanisms of Antigen Escape to Anti-BCMA and Anti-GPRC5D Targeted Immunotherapies in Multiple Myeloma

2023-03-20

Abstract excerpt

<title>Abstract</title> <p>B cell maturation antigen (BCMA) target loss is considered to be a rare event that mediates multiple myeloma (MM) resistance to anti-BCMA chimeric antigen receptor T cell (CAR T) or bispecific T cell engager (TCE) therapies. Emerging data report that downregulation of G protein coupled receptor family C group 5 member D (GPRC5D) protein often occurs at relapse after anti-GPRC5D CAR T. T...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 47093778-49d1-5049-ad51-61c8ffefafb4
DOI: 10.21203/rs.3.rs-2657360/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Tumor Intrinsic Mechanisms of Antigen Escape to Anti-BCMA and Anti-GPRC5D Targeted Immunotherapies in Multiple MyelomaDOI 10.21203/rs.3.rs-2657360/v1Read

Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myelomaSemantic proximity Read

Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma.Semantic proximity Read

Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape–Driven Relapse in Multiple MyelomaSemantic proximity Read

Genetic and epigenetic mechanisms of GPRC5D loss after anti-GPRC5D CAR T-cell therapy in multiple myelomaSemantic proximity Read

Timing antigenic escape in multiple myeloma treated with T-cell redirecting immunotherapiesSemantic proximity Read

Plasma cell identity escape drives resistance to anti-BCMA T-cell–redirecting therapy in multiple myelomaSemantic proximity Read

Single- and double-hit events in genes encoding immune targets before and after T cell–engaging antibody therapy in MMSemantic proximity Read

Multi-Omic Profiling Reveals Epigenetic Drivers of Immunotherapy Resistance in Multiple MyelomaSemantic proximity Read

Timing Genomic Antigen Loss in Multiple Myeloma Treated with T Cell-Redirecting Immunotherapies.Semantic proximity Read

Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivationSemantic proximity Read

PD1+TIGIT+2B4+KLRG1+ cells might underlie T-cell dysfunction in patients treated with BCMA-directed CAR-T therapySemantic proximity Read

Acquired resistance to bispecific antibodies by genetic or epigenetic inactivation of the target in multiple myelomaSemantic proximity Read